Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development
Zurich, Switzerland, May 3, 2023 – Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life science executive Ingrid Rauter as Head of R&D and Chief Medical Officer.
“I am excited to further contribute to Vaccentis as it is poised for a new phase in its product development and corporate growth. Working with the new agile leadership to progress the pipeline holds exciting prospects for patients and the company. VCC…”
Ingrid Rauter, PhD, has successfully led global research and clinical development programs for pipeline and marketed products for over ten years. She joins Vaccentis from at Amgen Inc., where her most recent role was as Global Medical Affairs Asset Lead Early Inflammation Pipeline. She also held key clinical development roles with increasing responsibilities at Takeda, Sandoz and Baxalta. Dr Rauter was honored by a prestigious fellowship in immunology at Harvard Medical School and has been recipient of scientific awards including the Herbert-Herxheimer Award of the German Society of Allergology and Clinical Immunology and the Erwin Schrödinger Fellowship of the Austrian Science Fund.
“I am delighted to welcome Dr Ingrid Rauter to Vaccentis as Chief Medical Officer and Head of R&D,” said Martin Munte, Chief Executive Officer of Vaccentis. “Ingrid brings a wealth of experience in biopharmaceutical industry R&D and medical affairs to Vaccentis. Over the last six months as an external consultant, she created a clear and compelling clinical and regulatory plan. Her expertise will especially inform and de-risk the late-stage clinical development of VCC-001, our autologous adjuvant renal tumor vaccine to treat non-metastatic renal cell carcinomas post-nephrectomy. She also will help us to leverage our autologous vaccine development platform to shape the Vaccentis pipeline strategy for future successes.”
The appointment further strengthens Vaccentis’ executive leadership team, following the July 2022 appointment of Martin Munte as CEO and the May 2022 appointments of three experienced entrepreneurs to the Board of Directors: Matthias Oertle, Marcel Frei and Subhasis Roy.